Avaliação Preliminar da Fampridina na Esclerose Múltipla: Para Além da Velocidade da Marcha

Jonathan Rios, José Luís Coelho, Sara Estrela Rego, Eduarda Afonso

Resumo


Introdução: É objetivo do estudo a avaliação do impacto da fampridina na velocidade da marcha, equilíbrio e perceção da capacidade de marcha em doentes com esclerose múltipla.

Material e Métodos: Estudo prospetivo, aberto, não controlado e não randomizado, em doentes com esclerose múltipla e escala Expandida do Estado de Incapacidade (EDSS) entre 4,0-7,0 sob tratamento com fampridina. Foram usados para a avaliação do impacto da fampridina: Multiple Sclerosis Walking scale 12 (MSWS-12), Timed 25-Foot Walk (T25FW), Timed Up and Go (TUG) e escala de Equilíbrio de Berg (EEB). A análise estatística foi efetuada com um nível de significância estatística de p < 0,05.

Resultados: Um total de 15 doentes (88,24%) foram considerados respondedores. A melhoria do equilíbrio, velocidade da marcha e perceção da capacidade para a marcha foi estatisticamente significativa com melhoria média de 19,08% (± 31,11) no T25FW (p = 0,022), 19,20% (± 26,13) na EEB (p = 0,012), 35,97% (± 34,93) no TUG (p = 0,022) e 12,99% (± 12,90) na MSWS-12 (p = 0,016). Há uma correlação forte e estatisticamente significativa entre TUG e T25FW (r = 0,668, p = 0,017).

Conclusão: Os resultados preliminares mostram a potencialidade da fampridina na melhoria da velocidade da marcha, equilíbrio e perceção da capacidade de marcha em doentes com esclerose múltipla. São necessários estudos para caracterizar os preditores de eficácia de resposta e avaliar o potencial do fármaco noutras áreas funcionais.


Palavras-chave


Equilíbrio; Esclerose Múltipla; Fampridina; Marcha

Texto Completo:

PDF

Referências


Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, et al. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurol. 2015;15:17.

Blight AR, Henney HR, Cohen R. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Ann N Y Acad Sci. 2014; 1329:33-44.

Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68: S22–S31.

Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite; a new clinical outcome measure for multiple sclerosis clinical trials. Mult Scler. 2002; 8: 359–65.

Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 433–40.

Pike J, Jones E, Rajagopalan K, Piercy J, Anderson P. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol. 2012; 12:94.

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, et al. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). CNS Neurosci Ther. 2013; 19: 302–6.

Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin. 2011; 27: 1415–23.

Krishnan AV, Kiernan MC. Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. Mult Scler. 2013; 19: 385–91.

Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014; 7: 97–113.

Chwieduk CM, Keating GM. Dalfampridine extended release: in multiple sclerosis, CNS Drugs. 2010; 24: 883–91.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 ; 68: 494-502.

Goodman AD, Brown TR, Krupp TR, Schapiro RT, Schwid SR, Cohen, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009; 373: 732-8.

Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015; 262: 1936-45.

Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35-40.

Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, et al., Longterm effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci. 2014; 337: 18–24.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two phase 3 clinical trials. Mult Scler. 2015; 21: 1322-31.

Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al., Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine, Mult Scler. 2001; 7: 354–8.

Jensen HB, Ravnborg M, Mamoei S, Dalgas U, Stenager U. Changes in cognition, arm function and lower body function after slow-release fampridine treatment. Mult Scler. 2014; 20: 1872-8.

Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, et al. Prolonged-release fampridine and walking and balance in MS: randomized controlled MOBILE trial. Mult Scler. 2016;22:212-21.

Khan F, Turner-Stokes L, Ng L, Kilpatrick T. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev. 2007;2:CD006036.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121–7.




DOI: http://dx.doi.org/10.25759/spmfr.265

Apontamentos

  • Não há apontamentos.


Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação